Clinical trials used doses as high as 1 mg per day without safety concerns, but 300 mcg is the most commonly referenced dose in peptide medicine literature and in the investigational protocols that have been published since the formal trials concluded
**Pediatric Patients:** Dosage should be determined by a healthcare professional based on the child's age, weight, and clinical condition
You are working with tiny volumes where small errors translate to meaningful dose variations
No human longevity outcome exists for any of these compounds, alone or blended
IGF-1 and its analogs including IGF-1 LR3 are listed under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and are prohibited at all times, in and out of competition
Always confirm the unit count with your prescriber before each injection and rotate injection sites between the abdomen, the front of the thighs, and the back of the upper arms to avoid lipohypertrophy